This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth (UNH) Closes DaVita Unit Buy, Expands OptumCare
by Zacks Equity Research
UnitedHealth's (UNH) purchase of DaVita Medical Group will likely aid the growth of OptumHealth, which is targeting double-digit percentage revenue long-term growth.
Tenet Healthcare Inks Deal to Offer Quality Health Services
by Zacks Equity Research
Tenet Healthcare (THC) enters into a contract with Aetna owing to which the company's healthcare services can be availed by Aetna members.
Healthcare Tumbles on Trump's Price Disclosure Order
by Sapna Bagaria
Hospital and health insurers' lose on Trump's executive order to unveil price of services to patients.
eHealth Surges 114% Year to Date: Will the Rally Continue?
by Zacks Equity Research
eHealth's (EHTH) operational excellence and growth initiatives help the stock continue the bull run.
The Hartford (HIG) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
The Hartford (HIG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
4 Insurance Picks As Fed Keeps Rate Unchanged, Hints Rate Cut
by Tanuka De
Investors may like to add insurance stocks with strong fundamentals and potential to generate better yields in the current scenario.
Why it is Worth Betting on Cigna Stock for Your Portfolio
by Zacks Equity Research
Banking on prudent buyouts and solid overseas business, Cigna (CI) holds immense potential to reap benefits for investors.
Are Investors Undervaluing Cigna (CI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Why Growth Investors Shouldn't Overlook Cigna (CI)
by Zacks Equity Research
Cigna (CI) possesses solid growth attributes, which could help it handily outperform the market.
Radian Group (RGA) Announces Pricing of $450M Senior Notes
by Zacks Equity Research
Radian Group (RDN) raised the size of the senior notes offering to $450 million from $350 million announced earlier and priced the same at a coupon rate of 4.875% per year.
Is Cigna (CI) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Cigna Corporation (CI) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Are Investors Undervaluing Cigna (CI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Why Cigna (CI) Is a Great Growth Stock
by Zacks Equity Research
Cigna (CI) possesses solid growth attributes, which could help it handily outperform the market.
Cigna (CI) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cigna (CI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Cigna, EOG Resources, Northrop Grumman, Sherwin-Williams and Eaton
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cigna, EOG Resources, Northrop Grumman, Sherwin-Williams and Eaton
Top Research Reports for Cigna, EOG Resources & Northrop Grumman
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cigna (CI), EOG Resources (EOG) and Northrop Grumman (NOC).
Bet on Top Stocks With Rising P/E to Enjoy Solid Gains
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat
by Zacks Equity Research
BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.
Are Investors Undervaluing Cigna (CI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna (CI) Beats Q1 Earnings Estimates, Raises 2019 View
by Zacks Equity Research
Cigna (CI) beats Q1 earnings estimates on revenue growth driven by the acquisition of Express Scripts.
Cigna (CI) Q1 Earnings Top Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.28% and -1.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Value Stocks to Buy for May 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, May 2nd
Zacks.com featured highlights include: Tenet, Tutor, CommScope and Cigna
by Zacks Equity Research
Zacks.com featured highlights include: Tenet, Tutor, CommScope and Cigna
What Awaits Berkshire Hathaway (BRK.B) This Earnings Season?
by Zacks Equity Research
Berkshire Hathaway's (BRK.B) first-quarter results are likely to benefit from improved performances across segments.
TESSCO (TESS) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
TESSCO (TESS) is actively pursuing strategies to capitalize on exciting growth opportunities in the marketplace, which is likely to drive its fiscal fourth-quarter results.